Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.
Marc J. Braunstein, MD, PhD, assistant professor in the Department of Medicine at NYU Long Island School of Medicine; course co-director of the Hematology-Oncology System and co-director of the Autologous Stem Cell Transplant Program, NYU Winthrop Hospital of NYU Langone Health’s Perlmutter Cancer Center, discusses updated results from the GRIFFIN trial in multiple myeloma.
The phase 2 GRIFFIN study evaluated the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) versus the standard triplet regimen of RVd in transplant-eligible patients with myeloma. The results showed an improvement in progression-free survival with the quadruplet. Additionally, the primary endpoint, which was stringent complete response (sCR), was superior at every evaluable timepoint in the quadruplet arm compared with the triplet arm.
The quadruplet could become the new standard of care for transplant-eligible patients, says Braunstein. However, longer-term follow-up data are needed in order to see which patient benefits the most from this treatment, concludes Braunstein.